3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Primary Myelofibrosis
28
Myeloproliferative Disorders
21
Polycythemia Vera
16
Thrombocythemia, Essential
7
Neoplasms
7
Pancreatic Neoplasms
6
Multiple Myeloma
6
Leukemia
6
Hematologic Diseases
5
Myelodysplastic Syndromes
4
Graft vs Host Disease
4
Colorectal Neoplasms
4
Bone Marrow Diseases
4
Thrombocytosis
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Bronchiolitis Obliterans Syndrome
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Lymphoma
2
Uveal Melanoma
1
Thalassemia
1
Recurrence
1
Preleukemia
1
Precancerous Conditions
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Interventions
pembrolizumab
98
Gemcitabine
70
Paclitaxel
59
Docetaxel
52
Carboplatin
49
Cisplatin
40
Nivolumab
39
Capecitabine
35
Pemetrexed
33
Fluorouracil
32
Bevacizumab
32
Cetuximab
31
130-nm albumin-bound paclitaxel
28
Trastuzumab
26
Irinotecan
24
Albumin-Bound Paclitaxel
24
Fulvestrant
22
Leucovorin
20
Oxaliplatin
18
Panitumumab
17
abemaciclib
16
Ipilimumab
16
Cyclophosphamide
15
cemiplimab
14
atezolizumab
14
Letrozole
14
palbociclib
12
Lapatinib
12
Drug Therapy
12
Doxorubicin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm Metastasis
×
ruxolitinib
×
Clear all
NCT06397313
2025-09-23
POTAMI-61
Ryvu Therapeutics SA
Phase 2
Recruiting
230 enrolled